Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.
about
Microfluidic synthesis of microfibers for magnetic-responsive controlled drug release and cell cultureComprehensive Map of Molecules Implicated in ObesityNovel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.The interconnectedness of cancer cell signaling.Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.Intra- and interspecies gene expression models for predicting drug response in canine osteosarcomaRole of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10Contemporary management of muscle-invasive bladder cancerDrug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Cancer subclonal genetic architecture as a key to personalized medicine.Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.Acridine and its derivatives: a patent review (2009 - 2013).Molecular markers in bladder cancer: Novel research frontiers.Integrative correlation: Properties and relation to canonical correlations.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationPrecision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.
P2860
Q28481700-53BE3B5F-4D60-4C96-9D5E-EA8C7EDCE7DFQ28550240-34D5CD8E-14AB-46FB-81FB-532E8C18D2BCQ34670535-4091A9D2-EB34-4290-BF6E-922E891A1AB1Q35669733-DDC5D000-EFCC-41A1-BC1A-F6E78E243DE4Q35671292-F92939FE-D79C-4899-8752-A8E5DA69878CQ35927860-2D7BB831-4FD0-42CD-B619-35C0D4E0B582Q36174250-F37C7294-1385-4CE5-A0AE-02F20F8D1597Q36389716-0F210099-D76F-406E-B93E-F4A34CB95DE1Q36406956-FF88D6CC-7FF7-42DA-A31C-5A69F34B475AQ37448116-6AEF9C54-1EBB-4AC6-A757-F7D24AA4AE66Q38195217-A599244F-0B2E-4FA3-B0D0-7E2BF79CA7F8Q38213469-EAD20512-BF01-4F17-A044-CE75D81CC260Q38520403-AE6062EE-0BEC-4C33-82B1-CAD3DF935BA8Q41243909-022C6C53-C2A8-446A-9AE8-D9A4105B9324Q41879186-5789F7B7-E271-4522-BF2A-259FA80B8D0CQ47406496-BBCB4056-6D18-407E-AC84-2D8563B8B22DQ55397522-00C9BFCE-504D-48F8-B28F-C0ACBF8F18F4
P2860
Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Use of yeast chemigenomics and ...... aluation of anticancer agents.
@ast
Use of yeast chemigenomics and ...... aluation of anticancer agents.
@en
type
label
Use of yeast chemigenomics and ...... aluation of anticancer agents.
@ast
Use of yeast chemigenomics and ...... aluation of anticancer agents.
@en
prefLabel
Use of yeast chemigenomics and ...... aluation of anticancer agents.
@ast
Use of yeast chemigenomics and ...... aluation of anticancer agents.
@en
P2093
P2860
P356
P1433
P1476
Use of yeast chemigenomics and ...... aluation of anticancer agents.
@en
P2093
Alexander S Baras
Dan Theodorescu
Daniel J Burke
Dmytro M Havaleshko
Kihyuck Moon
Stefan Bekiranov
Steven C Smith
P2860
P356
10.1593/NEO.101214
P577
2011-01-01T00:00:00Z